

APPENDIX, SUPPLEMENTARY FILE

Table 1 *Neisseria gonorrhoeae* isolates from foreign-born and native patients in countries reporting country of birth, Euro-GASP 2010-2014

COUNTRIES REPORTING COUNTRY OF BIRTH	FOREIGN BORN No. (%)	NATIVE No. (%)	TOTAL No. (%)
THE NETHERLANDS	246 (34.9)	577 (17.0)	823 (20.1)
IRELAND	92 (13.1)	162 (4.8)	254 (6.2)
UNITED KINGDOM	91 (12.9)	216 (6.4)	307 (7.5)
GREECE	86 (12.2)	315 (9.3)	401 (9.8)
ITALY	75 (10.7)	293 (8.6)	368 (9.0)
DENMARK	52 (7.4)	389 (11.5)	441 (10.8)
MALTA	19 (2.7)	58 (1.7)	77 (1.9)
SLOVAKIA	10 (1.4)	493 (14.5)	503 (12.3)
BELGIUM	10 (1.4)	104 (3.1)	114 (2.8)
SLOVENIA	9 (1.3)	197 (5.8)	206 (5.0)
GERMANY	7 (1.0)	61 (1.8)	68 (1.7)
HUNGARY	4 (0.6)	131 (3.9)	135 (3.3)
CYPRUS	3 (0.4)	29 (0.9)	32 (0.8)
PORTUGAL	0 (0.0)	369 (10.9)	369 (9.0)
TOTAL	704 (100.0)	3394 (100.0)	4098(100.0)

Table 2 Antimicrobial resistance and decreased susceptibility to ceftriaxone by known country of birth, Euro-GASP isolates 2010-2014

	FOREIGN BORN, No. (%)	NATIVES, No. (%)	UNKNOWN COUNTRY OF BIRTH, No. (%)	TOTAL, No (%)
CIPROFLOXACIN RESISTANT (n=9519)	326 (46.3)	1693 (50.0)	2791 (51.4)	4810 (50.5)
AZITHROMYCIN RESISTANT (n=9479)	50 (7.2)	251 (7.5)	283 (5.2)	584 (6.2)
CEFIXIME RESISTANT (n=9479)	25 (3.6)	192 (5.7)	289 (5.3)	506 (5.3)
CEFTRIAXONE RESISTANT (n=9529)	0 (0.0)	4 (0.1)	21 (0.4)	25 (0.3)
DECREASED SUSCEPTIBILITY TO CEFTRIAXONE (n=9529)	20 (2.8)	63 (1.9)	113 (2.1)	196 (2.1)
PENICILLINASE PRODUCTION (n=8560)	57 (11.7)	240 (8.4)	708 (13.6)	1005 (11.7)
RESISTANT ISOLATES (n=9529)	366 (52.0)	1817 (53.5)	3030 (55.8)	5213 (54.7)

Table 3 Epidemiological characteristics of antimicrobial resistant Euro-GASP isolates (n=5213) by country of birth, 2010-2014

	COUNTRY OF BIRTH		
	UNKNOWN COUNTRY OF BIRTH	FOREIGN BORN	NATIVES
YEAR OF DIAGNOSIS (n=5213)			
2010	733 (24.2)	31 (8.5)	225 (12.4)
2011	521 (17.2)	66 (18.0)	383 (21.1)
2012	552 (18.2)	99 (27.0)	393 (21.6)
2013	578 (19.1)	84 (23.0)	443 (24.4)
2014	646 (21.3)	86 (23.5)	373 (20.5)
AGE (years) (n=5046)			
<25	828 (28.7)	96 (26.3)	459 (25.5)
25-44	1589 (55.2)	231 (63.3)	1033 (57.4)
≥45	464 (16.1)	38 (10.4)	308 (17.1)
AREA OF ORIGIN (n=704)			
EU/EEA	-	118 (32.2)	-
Non-EU/EEA WHO EUR	-	72 (19.7)	-
WHO EMR	-	57 (15.6)	-
WHO AMRO	-	68 (18.6)	-
WHO AFR	-	22 (6.0)	-
WHO SEAR	-	14 (3.8)	-
WHO WPR	-	15 (4.1)	-
SEXUAL ORIENTATION (n=2666)			
Heterosexual females	189 (20.3)	29 (8.5)	169 (12.1)
Heterosexual males	407 (43.8)	158 (46.2)	637 (45.7)
Men who have sex with men	333 (35.8)	155 (45.3)	589 (42.2)
ISOLATION SITE (n=4852)			
Ano-rectal	208 (7.6)	66 (18.4)	195 (11.0)
Urogenital	2392 (87.8)	268 (74.7)	1484 (83.9)
Pharyngeal	125 (4.6)	25 (7.0)	89 (5.0)
HIV STATUS (n=1726)			
Positive	72 (21.8)	42 (15.8)	144 (12.7)
Negative	258 (78.2)	223 (84.2)	987 (87.3)

PREVIOUS GONORRHOEA (n=2042)			
Yes	161 (28.5)	31 (12.8)	181 (14.7)
No	403 (71.5)	212 (87.2)	1054 (85.3)
PROBABLE COUNTRY OF INFECTION (n=1794)			
Reporting country	428 (91.8)	162 (89.0)	1081 (94.3)
Other country	38 (8.2)	20 (11.0)	65 (5.7)